Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Legend Biotech (LEGN – Research Report). The associated price target remains the same with $75.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Mitchell Kapoor has given his Buy rating due to a combination of factors that highlight Legend Biotech’s strong market position and growth potential. The company’s financial results for the first quarter of 2025 showed a significant increase in revenue, driven largely by its collaboration with Janssen on CARVYKTI, a promising treatment in the multiple myeloma space. Despite some manufacturing challenges, Legend’s financial health remains robust, with a substantial cash reserve expected to sustain operations until profitability is reached in mid-2026.
CARVYKTI’s market performance is particularly noteworthy, with strong demand and increasing patient volumes, especially in the second-line multiple myeloma setting. The treatment’s expansion into more countries and growing outpatient treatment numbers indicate its competitive edge. Furthermore, CARVYKTI’s efficacy and safety profile, along with its strategic positioning against competitors, reinforce its potential as a leading therapy in its class. These factors collectively support Kapoor’s optimistic outlook and Buy rating for Legend Biotech’s stock.
In another report released today, Barclays also maintained a Buy rating on the stock with a $94.00 price target.